title: Immunophenotyping is an independent factor for risk stratification in AML.
abstract: BACKGROUND
  Chromosomal abnormalities are one of the most important prognostic factors in acute myeloid leukemia (AML). However, only a limited number of patients have such informative chromosomal abnormalities. The prognostic value of immunophenotyping in this disease is still unclear.
  
  
  METHODS
  Seven hundred and eighty-three newly diagnosed AML patients treated in the German SHG-AML trials in 1991 and 1996 were analyzed with a panel of 33 antibodies. Expression was correlated to overall survival, complete remission-rate, and complete remission duration, and tested in a multivariate analysis including other clinical and biological markers.
  
  
  RESULTS
  With a median follow-up of 4.3 years, patients with AML blasts negative for CD9, CD11b, CD13, CD34, and CD41, or positive for CD15, CD33, CD38, CD64, and MPO had superior overall survival. This effect was associated with a significantly higher complete remission rate (CD13, CD34, CD41, and CD64) or a longer complete remission duration (CD9, CD11b, and CD64). Cox-regression analysis, including cytogenetic, morphologic, and biologic parameters showed CD9, CD13, CD34, and CD64 as independent factors for overall survival. These markers were used for a prognostic score. Patients were pooled in three groups with highly significant differences of overall survival. The prognostic relevance of this score was confirmed in patients with normal karyotype and/or in younger patients </= 60 years.
  
  
  CONCLUSIONS
  Immunophenotyping is not only helpful for diagnosis but is of independent significance for prognosis, and may be useful for risk stratification in AML patients.
authors.affiliation: Department of Medicine III, University of Erlangen-Nuremberg, Erlangen, Germany. Roland.Repp@med3.imed.uni-erlangen.de
authors.forename: R
authors.initials: R
authors.lastname: Repp
authors.forename: U
authors.initials: U
authors.lastname: Schaekel
authors.forename: G
authors.initials: G
authors.lastname: Helm
authors.forename: C
authors.initials: C
authors.lastname: Thiede
authors.forename: S
authors.initials: S
authors.lastname: Soucek
authors.forename: U
authors.initials: U
authors.lastname: Pascheberg
authors.forename: H
authors.initials: H
authors.lastname: Wandt
authors.forename: W
authors.initials: W
authors.lastname: Aulitzky
authors.forename: H
authors.initials: H
authors.lastname: Bodenstein
authors.forename: R
authors.initials: R
authors.lastname: Sonnen
authors.forename: H
authors.initials: H
authors.lastname: Link
authors.forename: G
authors.initials: G
authors.lastname: Ehninger
authors.forename: M
authors.initials: M
authors.lastname: Gramatzki
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016130:Immunophenotyping / Q000379:methods*; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis
chemical_list: D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D003630:Daunorubicin